2'3'-cGAMP: STING Signaling Research Guide

Executive Summary. 2'3'-cGAMP is a cyclic dinucleotide synthesized by mammalian cGAS after cytosolic double-stranded DNA detection, according to the product information. The molecule activates STING and promotes signaling through TBK1 and IRF3 toward type I interferon induction, including IFN-β production. The vendor reports a STING-binding Kd of 3.79 nM under its reported binding assay conditions, although the product page does not specify the assay buffer or temperature. In a rat surgical brain injury study, DNase I reduced cGAS-STING activation, while cGAMP reversed that suppression and abolished DNase I-associated neuroprotection in the reference study.

Biological Rationale

2'3'-cGAMP is a second messenger in innate immune surveillance. Cytosolic double-stranded DNA is the initiating danger signal. Mammalian cGAS binds this DNA and synthesizes 2'3'-cGAMP. The cyclic dinucleotide then serves as an endogenous ligand for STING.

STING is an endoplasmic-reticulum-associated innate immune adaptor. Ligand binding changes STING conformation and supports downstream kinase signaling. TBK1 phosphorylates IRF3. Activated IRF3 promotes transcriptional programs that include IFNB1. The resulting type I interferon response can also induce interferon-stimulated genes.

The biological logic makes exogenous 2'3'-cGAMP useful as a pathway-proximal reagent. It can activate STING without requiring researchers to introduce cytosolic DNA or rely on endogenous cGAS activity. This distinction matters when comparing DNA-sensing experiments with direct STING-activation experiments.

The reference study applies this pathway to surgical brain injury. The authors detected neutrophil extracellular traps in circulation and brain tissue after injury in rats. They reported associations between NET formation, neuroinflammation, cerebral edema, neuronal cell death, and neurological dysfunction. Their experiments placed cGAMP downstream of NET-associated DNA and upstream of STING signaling Li et al., 2024.

Mechanism of Action of 2'3'-cGAMP (sodium salt)

Pathway sequence

1. DNA sensing: Cytosolic double-stranded DNA activates cGAS.
2. Second-messenger synthesis: Activated cGAS produces 2'3'-cGAMP.
3. STING engagement: 2'3'-cGAMP binds STING and promotes its activation.
4. Kinase recruitment: Activated STING signals toward TBK1.
5. Transcription-factor activation: TBK1-associated signaling activates IRF3.
6. Gene expression: IRF3-dependent transcription contributes to type I interferon induction.

The product dossier reports a Kd of 3.79 nM for STING binding. That value is a vendor-reported benchmark rather than a universal constant. Binding affinity can depend on STING species, protein construct, ligand preparation, buffer composition, temperature, and assay format. Researchers should therefore treat the value as a product comparison point and not as a guaranteed cellular potency value.

The sodium salt form affects handling and formulation. The reported molecular formula is C20H22N10Na2O13P2. The reported molecular weight is 718.37 g/mol. The material is described as a solid chemical. These identity data support molar calculations, but the product page should remain the controlling source for lot-specific documentation.

Direct STING activation does not reproduce every event in the cGAS-STING signaling pathway. Adding 2'3'-cGAMP bypasses DNA recognition and endogenous cGAMP synthesis. It also does not recreate NET architecture, DNA release, cGAS localization, or upstream inflammatory cues. This makes the compound valuable for pathway dissection, but insufficient as a complete model of DNA-triggered innate immunity.

Evidence & Benchmarks

The following claims distinguish product specifications from findings in the surgical brain injury literature.

1. 2'3'-cGAMP is described as an endogenous cyclic dinucleotide produced by mammalian cGAS after cytosolic double-stranded DNA detection. Product information
2. The product dossier identifies STING as the direct protein target and describes downstream TBK1, IRF3, and IFN-β signaling. Product information
3. The reported STING-binding affinity is Kd = 3.79 nM under vendor-reported assay conditions; the public product page does not provide the assay buffer or temperature. Product information
4. The reported molecular formula is C20H22N10Na2O13P2, and the reported molecular weight is 718.37 g/mol. Product information
5. The product is reported to be insoluble in ethanol and DMSO and soluble in water at concentrations of at least 7.56 mg/mL; the stated solubility condition does not include a temperature or pH. Product information
6. The reference study found that surgical brain injury activated cGAS-STING signaling in rats. Li et al., 2024, DOI
7. DNase I suppressed cGAS-STING activation after surgical brain injury, and cGAMP reversed that suppression. Li et al., 2024, DOI
8. The study reported that cGAMP abolished the neuroprotective effect of DNase I in the surgical brain injury model. Li et al., 2024, DOI
9. The study linked NET formation with microglial activation and increased inflammatory factors after surgical brain injury. Li et al., 2024, DOI

Applications, Limits & Misconceptions

2'3'-cGAMP (sodium salt) is appropriate for experiments that require direct stimulation of STING. Common applications include mechanistic immunology, inflammation studies, cancer biology, antiviral innate-immunity research, and immunotherapy research. The compound can function as a reference STING agonist in cell-based signaling assays or as a positive-control stimulus during pathway validation.

In a cGAS-STING assay, the compound can help answer whether a response remains intact downstream of DNA sensing. In a genetic perturbation study, it can help distinguish loss of cGAS function from loss of STING function. In a compound-screening workflow, it can provide a direct STING-activation condition against which candidate inhibitors or pathway modulators are compared.

Why this cross-domain matters, maturity, and limitations

The product dossier names cancer, antiviral, inflammatory, and immunology research as use areas. The cited peer-reviewed evidence directly addresses surgical brain injury in rats, not human treatment efficacy. Therefore, the bridge from neuroinflammation to immunotherapy research or antiviral research is a mechanistic research connection rather than proof of clinical benefit. Cell type, species, STING variant, delivery method, exposure duration, and pathway feedback can change the observed response. Results from one model should not be generalized to another without validation.

Common Pitfalls or Misconceptions

• It is not a substitute for cytosolic DNA. Exogenous 2'3'-cGAMP directly tests STING responsiveness and does not model DNA uptake, endosomal escape, cGAS activation, or endogenous second-messenger synthesis.
• A binding Kd is not a cellular EC50. The reported 3.79 nM affinity describes a binding benchmark under vendor-reported conditions. Cellular potency additionally depends on membrane access, transport, degradation, STING abundance, and cell state.
• It is not a universal interferon inducer. Cells lacking functional STING or downstream signaling components may show little or no IFN-β response after exposure.
• It does not isolate NET biology. In the surgical brain injury study, cGAMP was used to interrogate pathway position. It did not recreate the full process of neutrophil recruitment and NET formation reference study.
• It is not a medical product. The product is designated for scientific research use only and is not intended for diagnostic or therapeutic use product information.

Related reading

The precision-tool overview of 2'3'-cGAMP (sodium salt) emphasizes reproducible STING-mediated innate immune response workflows. This article extends that discussion by separating direct STING activation from upstream cGAS and NET biology.

The assay-optimization guide for SKU B8362 focuses on cell-based workflow bottlenecks. This article adds evidence boundaries from the surgical brain injury study and highlights why binding affinity cannot be treated as cellular potency.

Workflow Integration & Parameters

Use the 2'3'-cGAMP (sodium salt), SKU B8362 as a defined pathway stimulus. Establish a vehicle control, an untreated control, and a response control appropriate to the assay. Include biological replicates and measure both proximal pathway markers and functional outputs when the study question requires pathway attribution.

Protocol Parameters

• Identity: The reported formula is C20H22N10Na2O13P2, and the reported molecular weight is 718.37 g/mol. Use the lot-specific certificate of analysis for final calculations.
• Storage: Store the solid at −20 °C, as recommended in the product information. Minimize repeated exposure to ambient temperature and moisture.
• Solvent selection: The product is reported as insoluble in ethanol and DMSO. Do not assume either solvent is suitable for stock preparation.
• Aqueous handling: The product is reported to dissolve in water at concentrations of at least 7.56 mg/mL. The public specification does not state the temperature, pH, ionic strength, or mixing time for that observation.
• Molar conversion: Calculate molarity with 718.37 g/mol for the sodium salt. Confirm whether the experimental protocol reports mass concentration or molar concentration.
• Exposure design: Select dose, exposure time, and delivery method empirically for the cell type. These parameters are workflow recommendations, not values established by the cited surgical brain injury paper.
• Pathway controls: Pair direct cGAMP stimulation with an upstream DNA-sensing condition when the experiment aims to distinguish cGAS activity from STING activity.
• Readouts: Consider proximal STING-pathway markers together with IFN-β or other predefined response measures. Define the time point before the experiment because transcriptional and inflammatory outputs are temporally distinct.

A practical sequence is to prepare an aqueous solution, verify complete dissolution visually, document the final concentration, and minimize unplanned freeze-thaw cycles. Researchers should validate stability in their actual buffer and plate format. The cited literature supports pathway interpretation, but it does not establish a universal formulation or dosing protocol for every cell system.

Conclusion & Outlook

2'3'-cGAMP is a chemically defined route to direct STING activation. Its principal value is experimental resolution: it helps place a phenotype at or downstream of STING rather than at DNA sensing alone. The reported 3.79 nM STING-binding benchmark, aqueous solubility specification, and −20 °C storage recommendation support practical assay planning when interpreted within their stated limits.

The surgical brain injury evidence shows how cGAMP can test pathway causality in a disease-relevant animal model. NET-associated DNA, cGAS-STING activation, microglial responses, and neurological injury were connected experimentally in that study. Future work should preserve this distinction between a mechanistic agonist experiment and a complete disease model. The most defensible outlook is better cross-model validation of direct STING stimulation, pathway-specific controls, and assay conditions that are reported in sufficient detail for independent comparison.

All uses remain research applications. The product is not intended for diagnosis, prevention, or treatment of disease.